406 related articles for article (PubMed ID: 31300270)
1. Nivolumab in patients with rare head and neck carcinomas: A single center's experience.
Kokkali S; Ntokou A; Drizou M; Perdikari K; Makaronis P; Katsarou E; Koufopoulos N; Tzovaras A; Ardavanis A
Oral Oncol; 2020 Feb; 101():104359. PubMed ID: 31300270
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
Ferris RL; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Harrington KJ; Kasper S; Vokes EE; Even C; Worden F; Saba NF; Docampo LCI; Haddad R; Rordorf T; Kiyota N; Tahara M; Lynch M; Jayaprakash V; Li L; Gillison ML
Oral Oncol; 2018 Jun; 81():45-51. PubMed ID: 29884413
[TBL] [Abstract][Full Text] [Related]
4. CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer.
Gillison ML; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Harrington KJ; Kasper S; Vokes EE; Even C; Worden F; Saba NF; Iglesias Docampo LC; Haddad R; Rordorf T; Kiyota N; Tahara M; Monga M; Lynch M; Li L; Ferris RL
Oncologist; 2018 Sep; 23(9):1079-1082. PubMed ID: 29866947
[TBL] [Abstract][Full Text] [Related]
5. Autoimmune-related encephalitis during treatment with nivolumab for advanced head and neck cancer: a case report.
Guidi A; Violati M; Blasi M; Ferrari E; Luciani A; Codecà C; Ferrari D
Tumori; 2020 Dec; 106(6):NP23-NP28. PubMed ID: 32851941
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.
Haddad R; Concha-Benavente F; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Kasper S; Vokes EE; Worden F; Saba NF; Tahara M; Jayaprakash V; Lynch M; Li L; Gillison ML; Harrington KJ; Ferris RL
Cancer; 2019 Sep; 125(18):3208-3218. PubMed ID: 31246283
[TBL] [Abstract][Full Text] [Related]
7. Squamous Cell Carcinomas of the Head and Neck Cancer Response to Programmed Cell Death Protein-1 Targeting and Differential Expression of Immunological Markers: A Case Report.
Merhi M; Raza A; Inchakalody VP; Nashwan AJJ; Allahverdi N; Krishnankutty R; Uddin S; Zar Gul AR; Al Homsi MU; Dermime S
Front Immunol; 2018; 9():1769. PubMed ID: 30108590
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of chemotherapy after progression with nivolumab in squamous cell carcinoma of the head and neck.
Suzuki S; Toyoma S; Tomizawa H; Yamada T; Iikawa N; Shiina K; Saito H; Koizumi K; Kawasaki Y; Yamada T
Auris Nasus Larynx; 2020 Jun; 47(3):485-488. PubMed ID: 31248647
[TBL] [Abstract][Full Text] [Related]
9. A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141.
Kiyota N; Hasegawa Y; Takahashi S; Yokota T; Yen CJ; Iwae S; Shimizu Y; Hong RL; Goto M; Kang JH; Sum Kenneth Li W; Ferris RL; Gillison M; Namba Y; Monga M; Lynch M; Tahara M
Oral Oncol; 2017 Oct; 73():138-146. PubMed ID: 28939066
[TBL] [Abstract][Full Text] [Related]
10. Salvage Chemotherapy After Nivolumab for Recurrent or Metastatic Head and Neck Carcinoma.
Fushimi C; Okamoto I; Matsuki T; Masubuchi T; Okada T; Sato H; Tsukahara K; Kondo T; Yamashita T; Hanyu K; Omura GO; Takahashi H; Tada Y; Miura K
Anticancer Res; 2020 Sep; 40(9):5277-5283. PubMed ID: 32878817
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use.
Ferris RL; Licitra L; Fayette J; Even C; Blumenschein G; Harrington KJ; Guigay J; Vokes EE; Saba NF; Haddad R; Ramkumar S; Russell J; Brossart P; Tahara M; Colevas AD; Concha-Benavente F; Lynch M; Li L; Gillison ML
Clin Cancer Res; 2019 Sep; 25(17):5221-5230. PubMed ID: 31239321
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab versus investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age.
Saba NF; Blumenschein G; Guigay J; Licitra L; Fayette J; Harrington KJ; Kiyota N; Gillison ML; Ferris RL; Jayaprakash V; Li L; Brossart P
Oral Oncol; 2019 Sep; 96():7-14. PubMed ID: 31422216
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea.
Kim H; Kwon M; Kim B; Jung HA; Sun JM; Lee SH; Park K; Ahn MJ
BMC Cancer; 2020 Aug; 20(1):727. PubMed ID: 32758163
[TBL] [Abstract][Full Text] [Related]
14. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.
Ghanizada M; Jakobsen KK; Grønhøj C; von Buchwald C
Oral Oncol; 2019 Mar; 90():67-73. PubMed ID: 30846179
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck.
Saada-Bouzid E; Peyrade F; Guigay J
Curr Opin Oncol; 2019 May; 31(3):146-151. PubMed ID: 30893146
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States.
Haddad R; Cohen EEW; Venkatachalam M; Young K; Singh P; Shaw JW; Korytowsky B; Abraham P; Harrington KJ
J Med Econ; 2020 May; 23(5):442-447. PubMed ID: 31928375
[No Abstract] [Full Text] [Related]
17. Different responses to nivolumab therapy between primary and metastatic tumors in a patient with recurrent hypopharyngeal squamous cell carcinoma.
Sato K; Ono T; Sato F; Kawahara A; Azuma K; Kawaguchi T; Akiba J; Umeno H
Oral Oncol; 2020 Feb; 101():104366. PubMed ID: 31300273
[TBL] [Abstract][Full Text] [Related]
18. Relationship between immune-related adverse events and the long-term outcomes in recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab.
Matsuo M; Yasumatsu R; Masuda M; Toh S; Wakasaki T; Hashimoto K; Taura M; Uchi R; Nakagawa T
Oral Oncol; 2020 Feb; 101():104525. PubMed ID: 31863963
[TBL] [Abstract][Full Text] [Related]
19. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
Ferris RL; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Harrington K; Kasper S; Vokes EE; Even C; Worden F; Saba NF; Iglesias Docampo LC; Haddad R; Rordorf T; Kiyota N; Tahara M; Monga M; Lynch M; Geese WJ; Kopit J; Shaw JW; Gillison ML
N Engl J Med; 2016 Nov; 375(19):1856-1867. PubMed ID: 27718784
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.
Kato K; Cho BC; Takahashi M; Okada M; Lin CY; Chin K; Kadowaki S; Ahn MJ; Hamamoto Y; Doki Y; Yen CC; Kubota Y; Kim SB; Hsu CH; Holtved E; Xynos I; Kodani M; Kitagawa Y
Lancet Oncol; 2019 Nov; 20(11):1506-1517. PubMed ID: 31582355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
